arrow Log In to View Account     |      
HOME
Johns Hopkins Medicine
Hopkins Logo


|
 

 

Presented by the Johns Hopkins University School of Medicine.
Supported by an educational grant from Lilly USA, LLC.


OVERVIEW

Recent advances in the recognition of histologic subtypes as prognostic and predictive factors in nonsmall cell lung cancer (NSCLC) have created a new era of personalized therapy for patients with this disease. According to the latest data, the histologic subtype of NSCLC may influence a patient’s treatment regimen and, in turn, survival outcome. As a result, the National Comprehensive Cancer Network recommends the use of histology and biomarkers as predictive factors when selecting therapy for certain patients. Another recent development in the treatment of patients with advanced NSCLC is the discovery that maintenance chemotherapy is effective for some following first-line chemotherapy. In treating these patients, the variety and range of complicating factors can perplex even the best-educated physicians. Given the clinical impact of recent developments in NSCLC, clinicians require education to increase their knowledge, competence, and performance in using therapies to manage patients with NSCLC and to promote closer relationships within the multidisciplinary teams to optimize patient outcomes.

GOAL

This activity will focus on personalized therapy for patients with advanced NSCLC based on histology and gene expression profiling.

TARGET AUDIENCE

Clinicians who attended the International Association for the Study of Lung Cancer’s 14th World Conference on Lung Cancer and who treat patients with NSCLC. No prerequisites required.

LEARNING OBJECTIVES

After completing this activity, the participant will demonstrate the ability to:

  • DESCRIBE the prognostic and predictive role of histologic features and immunohistochemical markers in NSCLC therapy and how gene expression profiling and mutation analysis may help to customize therapy for patients with NSCLC.
  • ASSESS current and emerging therapeutic strategies based on tumor biology that incorporate targeted agents with chemotherapy for patients with advanced NSCLC.
  • APPLY techniques that improve interprofessional communication to maintain continuity of care and relay treatment expectations to patients with NSCLC.

The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.

ACCREDITATION STATEMENT

The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

After reviewing this online activity, participants may receive credit by completing the CME test, evaluation, and receiving a score of 70% or higher.

The estimated time to complete this activity: 1.5 hours.

Release date: October 15, 2011. Expiration date: October 15, 2013.

ACTIVITY FORMAT

This archived live meeting features expert faculty presenting brief lectures, case studies (in the form of tumor boards), stereoscopic 3-dimensional (3D) animation, discussions, interactive questions polled to the audience, and a faculty panel with a question and answer session.

This presentation was selected by the 14th World Conference on Lung Cancer (WCLC) Programme Committee as an independent educational activity held in conjunction with the 14th WCLC. This presentation is not sponsored or endorsed by the International Association for the Study of Lung Cancer.

FULL DISCLOSURE POLICY AFFECTING CME ACTIVITIES

As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) to require signed disclosures of the existence of financial relationships with industry from any individual in a position to control the content of a CME activity sponsored by OCME. Members of the Planning Committee are required to disclose all relationships regardless of their relevance to the content of the activity. Faculty are required to disclose only those relationships that are relevant to their specific presentation. The following relationships have been reported for this activity:

David S. Ettinger, MD (Chair/Planner)
Alex Grass Professor of Oncology
Johns Hopkins University School of Medicine
Baltimore, Maryland

Silvia Novello, MD, PhD
Assistant Professor
Thoracic Oncology Unit
University of Turin
San Luigi Hospital
Turin, Italy

Jyoti D. Patel, MD (Planner)
Associate Professor
Department of Medicine
Hematology Oncology Division
Northwestern University
Feinberg School of Medicine
Chicago, Illinois

William D. Travis, MD
Attending Thoracic Pathologist
Department of Pathology
Memorial Sloan Kettering Cancer Center
New York, New York

SPEAKERS
Dr Ettinger reports serving as a consultant for Biodesix, Boehringer Ingelheim, Daiichi Sankyo Company, Ltd, Lilly USA, LLC, Genentech, Inc, Merck & Co, Inc, Novartis Pharmaceuticals Corporation, Poniard Pharmaceuticals, Prometheus, Inc, Shin Nippon Biomedical Laboratories, Ltd, and Telik, Inc.

Dr Patel reports serving as an advisor for Genentech, Inc.


No other speakers have indicated that they have any financial interests or relationships with a commercial entity whose products or services are relevant to the content of their presentation(s).

PLANNERS
Dr Ettinger reports serving as a consultant for Biodesix, Boehringer Ingelheim, Daiichi Sankyo Company, Ltd, Lilly USA, LLC, Genentech, Inc, Merck & Co, Inc, Novartis Pharmaceuticals Corporation, Poniard Pharmaceuticals, Prometheus, Inc, and, Shin Nippon Biomedical Laboratories, Ltd, and Telik, Inc.

Dr Patel reports serving as an advisor for Genentech, Inc.


No other planners have indicated that they have any financial interests or relationships with a commercial entity.

Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution that receives the grant, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

OFF-LABEL PRODUCT DISCUSSION

No faculty member has indicated that their presentation will include information on off-label products.

DISCLAIMER

The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.

INTERNET CME POLICY

The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protect the privacy of its members and customers. Johns Hopkins University SOM CME maintains its Internet site as an information resource and service for physicians, other health professionals, and the public. Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet based activity. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine’s CME activity. CME collects only the information necessary to provide you with the services that you request.

CONFIDENTIALITY DISCLAIMER FOR CME ACTIVITY PARTICIPANT

I certify that I am participating in this Johns Hopkins University School of Medicine activity for CME-accredited training and/or educational purposes.

I understand that while I am participating in this capacity, I may be exposed to "protected health information," as that term is defined and used in Johns Hopkins policies and in the federal HIPAA privacy regulations (the "Privacy Regulations"). Protected health information is information about a person’s health or treatment that identifies the person. I also understand that while I am participating in this capacity I will be treated as a temporary member of Johns Hopkins for purposes of the Privacy Regulations only.

I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential.

I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone: 410-735-6509, e-mail: HIPAA@jhmi.edu.

“The Office of Continuing Medical Education at the Johns Hopkins University School of Medicine, as sponsor of this activity, has relayed information with the CME attendees/participants and certify that the visitor is here for training, education and/or observation purposes only.”

Johns Hopkins University School of Medicine
Office of Continuing Medical Education
720 Rutland Avenue/ Turner 20
Baltimore, Maryland 21205-2195
Reviewed & Approved by: General Counsel, Johns Hopkins Medicine (4/1/09)

HARDWARE & SOFTWARE REQUIREMENTS

Pentium 800 processor or greater, Windows 98/NT/200/XP or Mac OS 9/X or later, Microsoft Internet Explorer, Safari, Firefox, Windows Media Player 9.0 or later Flash player, 128 MB of RAM Monitor settings: High color at 800 x 600 pixels, Sound card and speakers, Adobe Acrobat Reader.

ACTIVITY

Instructions
Please complete the pre-test, listen to and watch the following presentations, and complete the post-test and evaluation to receive CME credit for this activity.

Pre-Test

Pathology and Molecular Markers for NSCLC

William D. Travis, MD

First-Line and Targeted Therapy for NSCLC
Jyoti D. Patel, MD

Maintenance and Duration of Therapy for NSCLC
Silvia Novello, MD, PhD

Questions and Answers
Faculty Panel

Tumor Board Discussion
David S. Ettinger, MD

Post-Assessment

procced to pretest




Johns Hopkins Advanced Studies in Medicine (ISSN-1558-0334), is published by Galen Publishing, LLC, d/b/a ASiM, PO Box 340, Somerville, NJ 08876. (908) 253-9001. Copyright ©2012 by Galen Publishing. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. ASiM is a registered trademark of The Healthcare Media Group, LLC.